Erythroid response rates
| . | n . | IWG 2000 HI-E . | IWG 2000-MER . | IWG 2006 HI-E . |
|---|---|---|---|---|
| Lenalidomide monotherapy (N = 39) | ||||
| Del(5q) | 7 | 6 (85.7%) | 6 (85.7%) | 6 (85.7%) |
| Non-del(5q) | 32 | 8 (25.0%) | 7 (21.9%) | 6 (19%) |
| 10 mg | 17 | 3 (17.6%) | 2 (11.8%) | |
| 15 mg | 15 | 5 (33.3%) | 5 (33.3%) | |
| Combination therapy | 23 | 6 (26.0%) | 5 (21.7%) | |
| Del(5q) | 4 | 2 (50.0%) | 1 (25.0%) | 1 (25.0%) |
| Non-del(5q) | 19 | 4 (21.1%) | 4 (21.1%) | 3 (16%) |
| 10 mg | 9 | 2 (22.2%) | 2 (22.2%) | |
| 15 mg | 10 | 2 (20.0%) | 2 (20.0%) |
| . | n . | IWG 2000 HI-E . | IWG 2000-MER . | IWG 2006 HI-E . |
|---|---|---|---|---|
| Lenalidomide monotherapy (N = 39) | ||||
| Del(5q) | 7 | 6 (85.7%) | 6 (85.7%) | 6 (85.7%) |
| Non-del(5q) | 32 | 8 (25.0%) | 7 (21.9%) | 6 (19%) |
| 10 mg | 17 | 3 (17.6%) | 2 (11.8%) | |
| 15 mg | 15 | 5 (33.3%) | 5 (33.3%) | |
| Combination therapy | 23 | 6 (26.0%) | 5 (21.7%) | |
| Del(5q) | 4 | 2 (50.0%) | 1 (25.0%) | 1 (25.0%) |
| Non-del(5q) | 19 | 4 (21.1%) | 4 (21.1%) | 3 (16%) |
| 10 mg | 9 | 2 (22.2%) | 2 (22.2%) | |
| 15 mg | 10 | 2 (20.0%) | 2 (20.0%) |